SWAV Shockwave Medical

Shockwave Medical Provides Quarterly Earnings Release Dates for 2024

Shockwave Medical Provides Quarterly Earnings Release Dates for 2024

SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:

Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET)

First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET)

Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET)

Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET)

Investors interested in listening to the fourth quarter 2023 earnings conference call at 4:30 p.m. eastern time on Thursday, February 15, 2024, may do so by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096. Live and archived webcasts of all earnings events will also be made available at .

Dial-in information for future earnings calls will be provided at later dates.

About Shockwave Medical, Inc.

Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in Europe. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at  and .

Media Contact:

Scott Shadiow

Investor Contact:

Debbie Kaster



EN
08/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shockwave Medical

 PRESS RELEASE

Shockwave Medical Reports First Quarter 2024 Financial Results

Shockwave Medical Reports First Quarter 2024 Financial Results SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said...

 PRESS RELEASE

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-W...

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch